NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2071.40 -0.20 (-0.01%)

695.4K NSE+BSE Volume

NSE 27 Nov, 2025 3:53 PM (IST)

94,613.7

Market Cap

High in industry

Beta 1Year

Low volatility

Analyst Upgrade

Geojit BNP Paribas upgrades Lupin to a 'Buy' call, expects a revenue CAGR of 10.2% over FY26-27 See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

25 Nov 2025

2071.40

-0.01%

LUPIN LIMITED

Buy: Lupin Ltd.

Recommendation Target

Geojit BNP Paribas

In Q2FY26, Lupin reported a consolidated revenue of Rs. 7,048cr, up 24.2% YoY, Lupin's India segment revenue rose 3.4% YoY to Rs. 2,078cr, led by an 8.8% growth in Rx business, strong chronic therapy momentum and robust volume growth,...

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

13 Nov 2025

2071.40

-0.01%

Record quarter with broad-based growth, strong U.S. momentum, and sharp margin expansion

Buy: Lupin Ltd.

Deven Choksey

Lupin remains well-positioned to sustain its strong growth trajectory, supported by a healthy specialty pipeline in the U.S., improved product mix, and operating leverage gains.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

11 Nov 2025

2071.40

-0.01%

Lupin Ltd

Buy: Lupin Ltd.

Recommendation Target

ICICI Direct

Niche launches in the US drive numbers; future pipeline key for sustainability Earning momentum strong till FY26; apparent slowdown in FY27 but pipeline buildup to continue- Strong growth was attributable US launches under exclusivity (gMyrbetriq, gTolvaptan and gSpiriva) and launches across regions. India was impacted due to lower tender sales in Institutional business. The company has maintained the strong EBITDA margins trajectory mainly driven by strong GPM performance. The...

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

10 Nov 2025

2071.40

-0.01%

Lupin (LPC IN) Q2FY26 Result Update Strong beat...

Buy: Lupin Ltd.

Prabhudas Lilladhar

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

09 Nov 2025

2071.40

-0.01%

Strong quarter, grim outlook on pipeline

Hold: Lupin Ltd.

ICICI Securities Limited

Lupin delivered a beat of 9.5%/26.3%/21.8% in revenue/EBITDA/PAT vs our estimates in Q2FY26, driven by exclusive products like Tolvaptan and Mirabegron.

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

08 Nov 2025

2071.40

-0.01%

Record US sales/emerging market recovery boosts earnings

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered better-than-expected performance for the quarter, with a 9%/30%/28% beat on revenue/EBITDA/PAT.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

21 Aug 2025

2071.40

-0.01%

Braving sector headwinds

Buy: Lupin Ltd.

Sharekhan

A shift to complex drugs in recent times in the US led to revenue and PAT CAGRs of 21.93% and 64.18% over FY22 to FY25.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

07 Aug 2025

2071.40

-0.01%

Another quarter, another earnings beat

Buy: Lupin Ltd.

Target

Emkay

Lupin delivered yet another quarter of earnings outperformance vs street as well as our estimates, with the beat in 1QFY26 being driven by a higher gross margin.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

07 Aug 2025

2071.40

-0.01%

Lupin (LPC IN) Q1FY26 Result Update Multiple growth...

Buy: Lupin Ltd.

Prabhudas Lilladhar

Lupin's (LPC) Q1FY26 EBITDA stood at Rs16.4bn (up 28% YoY) was in line with our estimates on the back of higher US sales supported by niche launches (gTolvaptan). LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23-24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY26E and FY27E broadly remain...

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

07 Aug 2025

2071.40

-0.01%

Risk towards exclusive products emerging; valuation attractive

Hold: Lupin Ltd.

Recommendation Target

ICICI Securities Limited

Lupin’s Q1FY26 result was largely in-line with our estimates. Launch of Tolvaptan in US (180 days exclusivity) helped Lupin offset the impact of price erosion in its US portfolio and a muted performance in India.

Lupin Ltd. is trading above all available SMAs

Is Lupin Ltd. worth buying?

931 Votes:

Buy 72.72%

Sell 17.62%

Hold 9.67%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf